Lung cancer cytology and small biopsy specimens: diagnosis, predictive biomarker testing, acquisition, triage, and management

Simon Sung, Jonas J. Heymann, John P. Crapanzano, Andre L. Moreira, Catherine Shu, William A. Bulman, Anjali Saqi

Research output: Contribution to journalReview articlepeer-review

1 Scopus citations

Abstract

In the 21st century, there has been a dramatic shift in the management of advanced-stage lung carcinoma, and this has coincided with an increasing use of minimally invasive tissue acquisition methods. Both have had significant downstream effects on cytology and small biopsy specimens. Current treatments require morphologic, immunohistochemical, and/or genotypical subtyping of non-small cell lung carcinoma. To meet these objectives, standardized classification of cytology and small specimen diagnoses, immunohistochemical algorithms, and predictive biomarker testing guidelines have been developed. This review provides an overview of current classification, biomarker testing, methods of small specimen acquisition and triage, clinical management strategies, and emerging technologies.

Original languageEnglish (US)
Pages (from-to)332-345
Number of pages14
JournalJournal of the American Society of Cytopathology
Volume9
Issue number5
DOIs
StatePublished - Sep 1 2020

Keywords

  • Biomarkers
  • Cytology
  • Emerging technologies
  • Lung cancer
  • Molecular testing
  • Small biopsy

ASJC Scopus subject areas

  • Pathology and Forensic Medicine

Fingerprint Dive into the research topics of 'Lung cancer cytology and small biopsy specimens: diagnosis, predictive biomarker testing, acquisition, triage, and management'. Together they form a unique fingerprint.

Cite this